Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Apr;478(4):707-717.
doi: 10.1007/s00428-020-02932-3. Epub 2020 Sep 21.

Association of tumor-infiltrating T lymphocytes with intestinal-type gastric cancer molecular subtypes and outcome

Affiliations

Association of tumor-infiltrating T lymphocytes with intestinal-type gastric cancer molecular subtypes and outcome

Naziha Mansuri et al. Virchows Arch. 2021 Apr.

Abstract

While host immune response is likely to be important for the prognosis of gastric cancer patients, detailed information on the T lymphocyte infiltration in different gastric cancer subtypes is lacking. Here, we studied the presence of CD3, CD8, and FOXP3 (Forkhead box p3) expressing T lymphocytes in a retrospective cohort of 190 intestinal gastric and gastroesophageal adenocarcinomas. The cancers represented four distinct molecular subtypes: Epstein-Barr virus-positive (EBV+), mismatch-repair-deficient (MMR-D), aberrant TP53, and the "other" subtype. The absolute numbers of CD3+, CD8+, and FOXP3+ T lymphocytes were analyzed in relation with these molecular subtypes and selected clinicopathological parameters. Overall, there was a large variation in the amount of infiltrating T lymphocyte in all molecular subtypes. Among the subtypes, EBV+ cancers differed from the other subtypes in increased lymphocyte infiltration and high CD8+/FOXP3+ ratio. While the TP53 aberrant subtype did not differ in the absolute amount of T lymphocyte, the ratio of CD8+/FOXP3+ and CD3+/FOXP3+ cells was highest in this subtype, possibly reflecting immunosuppression associated with genomic instability. Increased CD3+ and CD8+ T lymphocyte infiltrates were associated with better survival, and remained as independent prognostic factors in a multivariate analysis. This study is the first to investigate lymphocytic infiltration within four molecular subtypes of intestinal-type gastric cancer in a European cohort. The results provide an important addition to the current knowledge of T lymphocyte-dependent immune response in gastric cancer and its prognostic significance.

Keywords: Gastric cancer; Molecular subtypes; Overall survival; Tumor infiltration.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interests.

Figures

Fig. 1
Fig. 1
CD3, CD8, and FOXP3 T lymphocytes in four molecular subtypes of intestinal-type gastric adenocarcinoma. a Representative immunohistochemistry images of the different T lymphocyte subsets and corresponding hematoxylin-eosin images of gastric cancer tumor tissue (from left to right): CD3+ T lymphocytes, CD8+ cytotoxic T lymphocytes, and FOXP3+ regulatory T lymphocytes. Scale bar = 100 μm. bf Box plot visualization of T lymphocyte subsets in the different intestinal-type gastric cancer molecular subtypes. b CD3+ T lymphocytes. c. CD8+ T lymphocytes. d FOXP3+ T lymphocytes. e CD3+/FOXP3+ lymphocytes. f CD8+/FOXP3+ lymphocytes. Y-axis = number of lymphocytes/0.2mm2. Outliers are denoted with a circle.*p = 0.002, **p = 0.001, ***p < 0.0001
Fig. 2
Fig. 2
Kaplan-Meier analysis for recurrence-free survival and overall survival of patients with intestinal-type gastric cancer in relation to T lymphocyte infiltration. a Recurrence-free survival (CD3). b and c Overall survival (CD3 and CD8, respectively)

References

    1. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, Znaor A, Bray F. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144:1941–1953. doi: 10.1002/ijc.31937. - DOI - PubMed
    1. Ilhan-Mutlu A, Taghizadeh H, Beer A, Dolak W, Ba-Ssalamah A, Schoppmann SF, Hejna M, Birner P, Preusser M. Correlation of trastuzumab-based treatment with clinical characteristics and prognosis in HER2-positive gastric and gastroesophageal junction cancer: a retrospective single center analysis. Cancer Biol Ther. 2018;19:169–174. doi: 10.1080/15384047.2017.1414759. - DOI - PMC - PubMed
    1. Bilici A. Treatment options in patients with metastatic gastric cancer: current status and future perspectives. World J Gastroenterol. 2014;20:3905–3915. doi: 10.3748/wjg.v20.i14.3905. - DOI - PMC - PubMed
    1. Kim HJ, Oh SC. Novel systemic therapies for advanced gastric cancer. J Gastric Cancer. 2018;8:1–19. doi: 10.5230/jgc.2018.18.e3. - DOI - PMC - PubMed
    1. Fridman WH, Pagès F, Sauts-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12:298–306. doi: 10.1038/nrc3245. - DOI - PubMed

MeSH terms

Substances